echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Reduce the risk of early breast cancer recurrence by 42%

    Reduce the risk of early breast cancer recurrence by 42%

    • Last Update: 2022-01-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On November 30, 2021, AstraZeneca announced that the U.


    In 2020, approximately 2.


    BRCA is an important protein to repair cell DNA damage, and PARP also plays an important role in repairing DNA damage


    Previously, it has been approved by the US FDA to treat advanced ovarian cancer, breast cancer, pancreatic cancer and other cancer types that carry germline BRCA mutations


    This priority review qualification is awarded based on the positive results obtained in a phase 3 clinical trial


    Reference materials:

    [1] LYNPARZA® (olaparib) Granted Priority Review in the US for BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.